The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...

Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

A new treatment at Unity Point Health is offering promising results for those with irregular heartbeats, otherwise known as ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

The atrial fibrillation (AF) device market is experiencing rapid growth, fueled by the rising prevalence of atrial fibrillation, increasing awareness of early diagnosis, and advancements in medical ...

Current treatments for atrial fibrillation, particularly for patients living with obesity, have focused more on managing ...